Abstract
To explored the clinicopathological features of Luminal B-like breast cancer and analyze the value of St. Gallen consensus in its treatment. The patients with invasive breast cancer treated at our hospital between January 2010 and December 2012 were recruited and divided into five subtypes according to the criteria of St. Gallen International Expert Consensus report 2013. And their TNM stages, pathological characteristics and Ki-67 status were analyzed for Luminal B-like subtype. The Luminal B-like subtype was found in 390 patients (52.8%), human epidermalgrowth factor receptor 2(HER-2) positive in 89 patients (22.8%) and negative in 301 patients (77.2%).Only 7.3% required chemotherapy based upon the result of gene detection. Only those patients for whom the need of chemotherapy is to be determined shall really benefit from gene detection.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
